Skip to content
← Full study record

NCT00248560 · MORE INFO

Limitations, agreements, and source contact

Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer · Source last updated 2019-03-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
restrictive Agreement
false
limitations And Caveats
description
The trial design was changed during accrual to allow for study continuation although response rate was lower than predicted. The trial was completed but it did not meet the specified end points.
point Of Contact
email
sukaria@karmanos.org
organization
Barbara Ann Karmanos Cancer Institute
phone
313-576-8751
title
Ammar Sukari, M.D.
Complete source fields
certain Agreement
pi Sponsor Employee
true
restrictive Agreement
false
limitations And Caveats
description
The trial design was changed during accrual to allow for study continuation although response rate was lower than predicted. The trial was completed but it did not meet the specified end points.
point Of Contact
email
sukaria@karmanos.org
organization
Barbara Ann Karmanos Cancer Institute
phone
313-576-8751
title
Ammar Sukari, M.D.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice